康方生物Key data readouts for AK112 to validate

招银国际
Aug 28

一、公司财务与运营状况Akeso(9926HK)在2025年上半年实现产品销售收入14亿元人民币,同比增长49%,达到全年预测的43%,基本符合预期。AK104和AK112两款药物分别因纳入国家医保目录(NRDL),在二线及以上的宫颈癌和EGFR突变非小细胞肺癌治疗中推动了销售增长。预计到2026年,随着更多适应症进入NRDL,如一线胃癌、一线宫颈癌和PD-L1阳性非小细胞肺癌等,将进一步加速...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10